Pharmala Biotech Holdings Inc. (CSE:MDMA)

Revenue by Product

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
MDMA and MDXX	722.71K	Log In	Log In
MDMA and MDXX Growth	73.04%	Log In	Log In
License	224.34K	Log In	Log In
License Growth	96.17%	Log In	Log In
Consulting	88.25K	Log In	Log In

Revenue by Geography

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
Australia	844.71K	Log In	Log In
Canada	158.21K	Log In	Log In
Canada Growth	-70.26%	Log In	Log In
United States	32.38K	Log In	Log In